Recent Updates
Recently added Catalysts
RDY Neutral Sentiment

SECURITIES AND EXCHANGE COMMISSION

Key Takeaway: Dr. Reddy's Laboratories has filed a report as a foreign private issuer with the Securities and Exchange Commission under the Securities Exchange Act of 1934. The report indicates compliance with filing regulations, and the submission includes information pertinent to the registrant's activities and requirements. The filing was signed by K Randhir Singh, the Company's Secretary, and is dated October 24, 2025. This document serves as an important update in the company's regulatory obligations.
Price reaction · baseline $14.62 (2025-10-23 close) · hit after-hours · 1 other RDY headline(s) in the window, move may be shared
day 0 close
-0.3%

Market Sentiment Analysis

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+8%
120-day peak, hindsight
Typical move
1.3%
average across 4 past catalysts
Lead asset
DFD06
Phase 3 · Psoriasis

Full Press Release Details

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE
UNDER THE SECURITIES EXCHANGE ACT OF 1934
Commission File Number 1-15182
DR. REDDY'S LABORATORIES LIMITED
(Translation of registrant's name into English)
8-2-337, Road No. 3, Banjara Hills
Hyderabad, Telangana 500 034, India
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(1): ______
Note: Regulation S-T Rule 101(b)(1) only permits the submission
in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in
paper as permitted by Regulation S-T Rule 101(b)(7): ______
Note: Regulation S-T Rule 101(b)(7) only permits
the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must
furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on which the registrant's securities
are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the
registrant's security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other
Commission filing on EDGAR.
Indicate by check mark whether by furnishing the information
contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.
If "Yes" is marked, indicate below the file number assigned
to registrant in connection with Rule 12g3-2(b): 82-________.
Exhibit Number Description of Exhibits
99.1 Intimation dated October 24, 2025
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
DR. REDDY'S LABORATORIES LIMITED (Registrant)
Date: October 24, 2025 By: /s/ K Randhir Singh
Name: K Randhir Singh
Title: Company Secretary

Frequently Asked Questions

What is the purpose of the SEC filing?

The filing is a report by Dr. Reddy's Laboratories as required under the Securities Exchange Act.

Where is Dr. Reddy's Laboratories located?

Dr. Reddy's Laboratories is based in Banjara Hills, Hyderabad, Telangana, India.

What forms does Dr. Reddy's file with the SEC?

Dr. Reddy's submits Form 20-F, Form 40-F, and Form 6-K as needed.

Who signed the SEC report?

The report was signed by K Randhir Singh, the Company Secretary.

When was the SEC filing made?

The filing was made on October 24, 2025.

Last updated: Oct 24, 2025